Sun Pharma Gets CDSCO Panel Nod to Study Cyclosporine Ophthalmic Solution

Published On 2023-10-26 12:30 GMT | Update On 2023-10-26 12:30 GMT

New Delhi: The drug major Sun Pharma has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical trial of Cyclosporine Ophthalmic Solution 0.09%.

This came in line with the revised Phase IV clinical trial protocol presented by Sun Pharma before the committee.

Cyclosporine eye drops are used to increase tear production in patients who have a certain eye condition (eg, keratoconjunctivitis sicca). It is also used to treat vernal keratoconjunctivitis (allergic eye condition) and signs and symptoms of dry eye disease.

Cyclosporine is a potent immunomodulatory agent with an increasing number of clinical applications. Its major mode of action is inhibition of the production of cytokines involved in the regulation of T-cell activation. In particular, cyclosporine inhibits the transcription of interleukin.

Cyclosporine is a steroid-sparing immunosuppressant used in organ and bone marrow transplants as well as inflammatory conditions such as ulcerative colitis, rheumatoid arthritis, and atopic dermatitis.

At the recent SEC meeting for Ophthalmology held on 18th October 2023, the expert panel reviewed the revised Phase IV clinical trial protocol of Cyclosporine Ophthalmic Solution 0.09%.

After detailed deliberation, the committee recommended the grant of permission to conduct the Phase IV clinical trial as per the revised protocol (Protocol No. ICR/21/021, Version No. 2.0 Dated: 15.06.2023) presented by the firm.

Also Read:Revise Phase III CT protocol of Olokizumab as a single-arm study: CDSCO Panel Tells Dr Reddys

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma Gets CDSCO Panel Nod to Study Cyclosporine Ophthalmic Solution

Similar News

Merck receives positive EU CHMP opinion for Enflonsia for RSV in infants

Chennai Pharma Firm Under ED Net in Rs 637 Crore Bank Fraud Case

Biocon Gets CDSCO Panel Nod to Import Aflibercept Injection for Eye Disorders, Phase IV Trial Mandated

94 Drug, Medical Product Batches Fail CDSCO Quality Tests in August

Roche subcutaneous formulation of Lunsumio recommended by CHMP for EU nod for follicular lymphoma

Bayer new drug application for gadoquatrane accepted for review in China

JnJ gets positive CHMP opinion of nipocalimab for antibody-positive patients living with generalised myasthenia gravis

Allahabad HC Grants Relief to Pharma Firm Against Tax Notices